INFRASTRUCTURAL CAPABILITY OF INVESTIGATOR-INITIATED TRIALS INVOLVING UNAPPROVED INVESTIGATIONAL DRUGS IN JAPAN

被引：0
|
作者：
Shimizu, T. [1 ]
Kaneda, H. [1 ]
Tsurutani, J. [1 ]
Okamoto, K. [1 ]
Tanaka, K. [1 ]
Ohnishi, R. [1 ]
Nomura, M. [1 ]
Aida, H.
Hashii, C.
Nakagawa, K. [1 ]
机构：
[1] Kinki Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka 577, Japan
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
10.1093/annonc/mdt452.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Why do we need noncommercial, investigator-initiated clinical trials?
    Alan Tyndall
    Nature Clinical Practice Rheumatology, 2008, 4 : 354 - 355
  • [32] Innovative approaches to investigator-initiated, multicentre paediatric clinical trials in Canada
    Kelly, Lauren E.
    Richer, Lawrence
    Ali, Samina
    Plint, Amy C.
    Poonai, Naveen
    Freedman, Stephen B.
    Knisley, Lisa
    Shimmin, Carolyn
    Hickes, Serena
    t Jong, Geert W.
    Pechlivanoglou, Petros
    Offringa, Martin
    Lacaze, Thierry
    Klassen, Terry P.
    BMJ OPEN, 2019, 9 (06):
  • [33] Cost of insurance policies for investigator-initiated cancer clinical trials in Italy
    Perrone, F
    Marangolo, M
    Di Costanzo, F
    Colucci, G
    Repetto, L
    Merlano, M
    De Placido, S
    Torri, V
    Comella, G
    Labianca, R
    Parisi, V
    Gallo, C
    TUMORI JOURNAL, 2005, 91 (04): : 373 - 379
  • [34] Why do we need noncommercial, investigator-initiated clinical trials?
    Tyndall, Alan
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (07): : 354 - 355
  • [35] Investigator-Initiated Registration Directed Trials, or Advanced Medical Care conducted by GOTIC and NRG-Oncology Japan
    Fujiwara, Keiichi
    ANNALS OF ONCOLOGY, 2019, 30 : 28 - 28
  • [36] Trends in Investigator-Initiated Clinical Studies at a University Hospital after Enforcement of the 2018 Clinical Trials Act in Japan
    Sato, Yasutaka
    Sakaguchi, Satoshi
    Takechi, Kenshi
    Chuma, Masayuki
    Yagi, Kenta
    Kane, Chikako
    Goda, Mitsuhiro
    Hamano, Hirofumi
    Aoe, Yuki
    Nokihara, Hiroshi
    Kubo, Yoshiaki
    Hashimoto, Ichiro
    Yanagawa, Hiroaki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (03) : 374 - 377
  • [37] Lessons learnt from 15 years of investigator-initiated trials on axial spondyloarthritis
    Sieper, J.
    Braun, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2015, 74 (02): : 125 - 131
  • [38] Efficiency of eSource Direct Data Capture in Investigator-Initiated Clinical Trials in Oncology
    Yaegashi, Hiroko
    Hayashi, Yukikazu
    Takeda, Makoto
    Chiu, Shih-Wei
    Nakayama, Haruhiko
    Ito, Hiroyuki
    Takano, Atsushi
    Tsuboi, Masahiro
    Teramoto, Koji
    Suzuki, Hiroyuki
    Kato, Tatsuya
    Yasui, Hiroshi
    Nagamura, Fumitaka
    Daigo, Yataro
    Yamaguchi, Takuhiro
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (06) : 1031 - 1041
  • [39] Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model
    Georgias, Christine
    Grunow, Andrea
    Olderog, Miriam
    May, Alexander
    Paulus, Ursula
    CLINICAL TRIALS, 2012, 9 (06) : 781 - 787
  • [40] Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
    Bergmann, L.
    Berns, B.
    Dalgleish, A. G.
    von Euler, M.
    Hecht, T. T.
    Lappin, G. L.
    Reed, N.
    Palmeri, S.
    Smyth, J.
    Embacher-Aichorn, S.
    Zwierzina, H.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1573 - 1578
12345